Table 2 Univariate survival analyses.

From: Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma

Parameter

No. of Case

OS

LRFS

No. Event

P-value

No. Event

P-value

Sex

  

0.8128

  

Male

84

27

 

47

0.3931

Female

20

8

 

10

 

Age (years)

  

0.6115

 

0.1427

<60

48

15

 

22

 

60

56

20

 

35

 

Pugh-Child’s Classification

     

A

85

23

<0.0001*

43

<0.0001*

B

6

6

 

6

 

C

3

3

 

3

 

AFP

  

0.0556

 

0.1840

<400

75

19

 

37

 

400

23

10

 

14

 

Tumor Multiplicity

  

<0.0001*

 

<0.0001*

Solitary

61

8

 

22

 

Multiple

43

27

 

35

 

Differentiation

     

Well/Moderately differentiated

79

21

0.0010*

39

0.0015*

Poorly differentiated

25

14

 

18

 

Primary Tumor (pT)

  

0.0003*

 

0.0017*

pT1

42

6

 

16

 

pT2

32

13

 

20

 

pT3–4

30

16

 

21

 

AJCC Stage

  

<0.0001*

 

0.0003*

Stage I

40

4

 

14

 

Stage II

32

13

 

20

 

Stage III-V

32

18

 

23

 

CLIP score

  

0.0008*

 

0.0001*

0–1

63

15

 

29

 

2–3

30

16

 

22

 

Okuda stage

  

0.0005*

 

0.0748

I

62

14

 

31

 

II-III

31

17

 

20

 

IL-20

  

<0.0001*

 

<0.0001*

Low expression (<5%)

52

8

 

19

 

High expression (5%)

52

27

 

38

 
  1. AFP: alpha fetal protein OS: overall survival.
  2. LRFS: local recurrence free survival.
  3. CLIP: The Cancer of the Liver Italian Program.
  4. AJCC: The American Joint Committee on Cancer TNM system.